tirzepatide pills vs injections Compounded vs. Zepbound – Forbes Health Weight Loss Pill vs Injection

Key Highlights Three once-monthly injections achieved placebo-adjusted weight loss of up to 6.3% at Week 12, increasing to 7.5% at Week 16 Weight loss maintained up to 4 months after the final dose, supporting once-quarterly maintenance therapy potential No weekly lead-in dosing required, differentiating ASC30 from many current GLP-1 regimens Safety profile consistent with the GLP-1 class, with mild-to-moderate adverse events and no discontinuations Why It Matters: Convenience advantage: Monthly or quarterly dosing could significantly improve adherence vs weekly GLP-1 injections Small-molecule innovation: ASC30 is a GLP-1 biased small molecule, enabling both oral and injectable formulations Platform validation: Supports Ascletis Ultra-Long-Acting Platform (ULAP) for developing long-duration metabolic therapies Key Takeaway: ASC30 highlights the next frontier in obesity therapeuticsultra-long-acting incretin therapies

Volkow, Claus Thorn Ekstrm, Gitte Moos Knudsen, Tina Vilsbll, and Anders Fink-Jensen

Supplementary support includes metabolic boosters like lipotropic fat burners and B12 injections

Thermo-TRPs and gut microbiota are involved in thermogenesis and energy metabolism during low temperature exposure of obese mice

Ridha, S.G

In partnership with telehealth platform LifeMD, they launched the ASCEND GLP-1 Nutrition Support Plan and the GLP-1 Optimization Plan